Roth/MKM Starts Prenetics (PRE) at Buy

Roth/MKM analyst George Kelly initiates coverage on Prenetics (NASDAQ: PRE) with a Buy rating and a price target of $36.00.

The analyst comments: "We initiate coverage of Prenetics (PRE) with a Buy rating and a $36 PT. The company, which struggled to find its footing after completing its business combination with SPAC Artisan Acquisition Corp. in 2022, has found a winner in IM8, a supplement brand launched in late-2024. IM8 quickly scaled run-rate revenue to >$100mn and has now become management’s sole focus. The Street is starting to take note, but still underappreciates IM8’s growth potential and PRE’s asset-rich balance sheet, in our view. Our $36 PT is based on 2.5x 2026E revenue, inclusive of PRE's non-core assets."

For an analyst ratings summary and ratings history on Prenetics click here. For more ratings news on Prenetics click here.

Shares of Prenetics closed at $21.43 yesterday.

You May Also Be Interested In

• Jefferies Downgrades Apple (AAPL) to Underperform
• Cantor on Semis: 'we view the selloff as overdone'
• Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation